Solid Biosciences Inc (SLDB) Earnings

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The firm also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. The company also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.